Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Jan;49(1):10–14. doi: 10.1136/jcp.49.1.10

Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.

S Kitchen 1, I Jennings 1, T A Woods 1, F E Preston 1
PMCID: PMC1023149  PMID: 8666677

Abstract

AIM: To assess the sensitivity of activated partial thromboplastin time (APTT) reagents for monitoring heparin dosage using data from the UK National External Quality Assessment Scheme (NEQAS) for blood coagulation. METHODS: Data were reviewed from four surveys using samples prepared by addition of heparin to normal plasma in vitro and from two surveys in which samples were prepared using plasma from patients receiving heparin therapy (ex vivo samples). RESULTS: For both in vitro and ex vivo samples, notable differences between APTT reagents with respect to heparin sensitivity were noted. This indicates that a uniform therapeutic range of 1.5-2.5 calculated by the APTT ratio may not be appropriate for all reagents. Reagent sensitivity in ex vivo samples was substantially different to that in in vitro samples. CONCLUSIONS: The results of this large series of laboratories clearly indicate that reagent specific therapeutic ranges may be necessary, and that samples prepared by the addition of heparin to normal plasma in vitro can be misleading and should not be used.

Full text

PDF
10

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bain B., Forster T., Sleigh B. Heparin and the activated partial thromboplastin time--a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol. 1980 Nov;74(5):668–673. doi: 10.1093/ajcp/74.5.668. [DOI] [PubMed] [Google Scholar]
  2. Banez E. I., Triplett D. A., Koepke J. Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time. Am J Clin Pathol. 1980 Oct;74(4 Suppl):569–574. [PubMed] [Google Scholar]
  3. Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972 Aug 17;287(7):324–327. doi: 10.1056/NEJM197208172870703. [DOI] [PubMed] [Google Scholar]
  4. Brandt J. T., Triplett D. A. Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol. 1981 Oct;76(4 Suppl):530–537. [PubMed] [Google Scholar]
  5. CLAUSS A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957 Apr;17(4):237–246. doi: 10.1159/000205234. [DOI] [PubMed] [Google Scholar]
  6. Gallus A. S., Hirsh J., Gent M. Relevance of preoperative and postoperative blood tests to postoperative leg-vein thrombosis. Lancet. 1973 Oct 13;2(7833):805–809. doi: 10.1016/s0140-6736(73)90855-6. [DOI] [PubMed] [Google Scholar]
  7. Gawoski J. M., Arkin C. F., Bovill T., Brandt J., Rock W. A., Jr, Triplett D. A. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects. Arch Pathol Lab Med. 1987 Sep;111(9):785–790. [PubMed] [Google Scholar]
  8. Howarth S. Activated partial thromboplastin time reagents: an evaluation. Br J Biomed Sci. 1993 Jun;50(2):109–113. [PubMed] [Google Scholar]
  9. Hull R. D., Raskob G. E., Hirsh J., Jay R. M., Leclerc J. R., Geerts W. H., Rosenbloom D., Sackett D. L., Anderson C., Harrison L. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986 Oct 30;315(18):1109–1114. doi: 10.1056/NEJM198610303151801. [DOI] [PubMed] [Google Scholar]
  10. Hull R. D., Raskob G. E., Rosenbloom D., Panju A. A., Brill-Edwards P., Ginsberg J. S., Hirsh J., Martin G. J., Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med. 1990 May 3;322(18):1260–1264. doi: 10.1056/NEJM199005033221802. [DOI] [PubMed] [Google Scholar]
  11. Kitchen S., Walker I. D., Woods T. A., Preston F. E. Thromboplastin related differences in the determination of international normalised ratio: a cause for concern? Steering Committee of the UK National External Quality Assessment Scheme in Blood Coagulation. Thromb Haemost. 1994 Sep;72(3):426–429. [PubMed] [Google Scholar]
  12. Levine M. N., Hirsh J., Gent M., Turpie A. G., Cruickshank M., Weitz J., Anderson D., Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994 Jan 10;154(1):49–56. [PubMed] [Google Scholar]
  13. Ray M., Carroll P., Smith I., Hawson G. An attempt to standardize APTT reagents used to monitor heparin therapy. Blood Coagul Fibrinolysis. 1992 Dec;3(6):743–748. doi: 10.1097/00001721-199212000-00007. [DOI] [PubMed] [Google Scholar]
  14. Scialla S. J. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization. Am J Clin Pathol. 1985 Sep;84(3):351–354. doi: 10.1093/ajcp/84.3.351. [DOI] [PubMed] [Google Scholar]
  15. Shojania A. M., Tetreault J., Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol. 1988 Jan;89(1):19–23. doi: 10.1093/ajcp/89.1.19. [DOI] [PubMed] [Google Scholar]
  16. Turpie A. G., Robinson J. G., Doyle D. J., Mulji A. S., Mishkel G. J., Sealey B. J., Cairns J. A., Skingley L., Hirsh J., Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352–357. doi: 10.1056/NEJM198902093200604. [DOI] [PubMed] [Google Scholar]
  17. van den Besselaar A. M., Meeuwisse-Braun J., Bertina R. M. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost. 1990 Feb 19;63(1):16–23. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES